JPS6463525A - Alcoholic liver triglyceride increase-suppressing agent - Google Patents

Alcoholic liver triglyceride increase-suppressing agent

Info

Publication number
JPS6463525A
JPS6463525A JP63103661A JP10366188A JPS6463525A JP S6463525 A JPS6463525 A JP S6463525A JP 63103661 A JP63103661 A JP 63103661A JP 10366188 A JP10366188 A JP 10366188A JP S6463525 A JPS6463525 A JP S6463525A
Authority
JP
Japan
Prior art keywords
salt
increase
alcoholic liver
liver
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP63103661A
Other languages
Japanese (ja)
Inventor
Koji Nishigori
Yoshinobu Nagano
Ken Ikeda
Miyuki Iiizumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Priority to JP63103661A priority Critical patent/JPS6463525A/en
Publication of JPS6463525A publication Critical patent/JPS6463525A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PURPOSE:To obtain an alcoholic liver triglyceride increase-suppressing agent containing glutathione monoalkyl ester or salt thereof as an active ingredient, suppressing increase of triglyceride in liver and useful in prevention and remedy for liver disease. CONSTITUTION:The aimed product is obtained by containing glutathione monoalkyl ester or salt thereof as an active ingredient, blending the above- mentioned ester or salt with a conventional carrier for formulation, diluting agent, additives, etc., and formulating the blend according to ordinary method. The aimed product can be prepared in forms of tablet, inhalant, granule, capsule, ointment, liquid medicine, injection, etc., and is preferably administered in dose of 100-2,000mg/adult day in intravenous injection. The compound expressed by the formula is obtained by reacting a glutathione with an alcohol in the presence of an acid and as necessary subjecting the reaction product to desalt or salt formation treatment.
JP63103661A 1987-05-08 1988-04-26 Alcoholic liver triglyceride increase-suppressing agent Pending JPS6463525A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP63103661A JPS6463525A (en) 1987-05-08 1988-04-26 Alcoholic liver triglyceride increase-suppressing agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11202187 1987-05-08
JP63103661A JPS6463525A (en) 1987-05-08 1988-04-26 Alcoholic liver triglyceride increase-suppressing agent

Publications (1)

Publication Number Publication Date
JPS6463525A true JPS6463525A (en) 1989-03-09

Family

ID=26444275

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63103661A Pending JPS6463525A (en) 1987-05-08 1988-04-26 Alcoholic liver triglyceride increase-suppressing agent

Country Status (1)

Country Link
JP (1) JPS6463525A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016065A1 (en) * 1990-04-26 1991-10-31 Senju Pharmaceutical Co., Ltd. Hepatic disorder inhibitor
CN105166923A (en) * 2015-08-04 2015-12-23 苏州泽达兴邦医药科技有限公司 Health-care corn peptide food and making method

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016065A1 (en) * 1990-04-26 1991-10-31 Senju Pharmaceutical Co., Ltd. Hepatic disorder inhibitor
CN105166923A (en) * 2015-08-04 2015-12-23 苏州泽达兴邦医药科技有限公司 Health-care corn peptide food and making method

Similar Documents

Publication Publication Date Title
SK1594A3 (en) Novel compositions based on taxane class derivatives
CA1176567A (en) Pharmaceutical preparation
HUP0302726A2 (en) Methods of administering pharmaceutical composition containing epothilone analogs for the treatment of cancer and of preparation the same
JPS5923313B2 (en) (+) Water-soluble double salt of catechin and its production method
GB2037306A (en) Cyclodextrin-camomile inclusion complexes and pharmaceutical compositions containing them
US4784855A (en) Pharmaceutical compositions and suppository
US4291030A (en) Method of lowering blood cholesterol
JPS6463525A (en) Alcoholic liver triglyceride increase-suppressing agent
CA1313674C (en) Use of 1,3-butanediol acetoacetate in parenteral and enteral nutrition
US4973553A (en) Salt or organogermanium compound and medicine containing the same
GB1388330A (en) Method of preparing stable aqueous solutions of organosilicic compounds and the resulting products and applications thereof
US4742065A (en) Salts of basic caffeine-8-ethers and their use as pharmaceuticals
CA2434526A1 (en) Methods of administering epothilone analogs for the treatment of cancer
US4465673A (en) Pentagalloylglucose antiviral composition
US4389414A (en) Prostaglandin compositions
US5556862A (en) Pharmaceutical compositions containing isoquinoline derivatives
NL8101987A (en) THE COMPOUND 4-AMINO-1-BETA-D-RIBOFURANOSYL-1H-IMIDAZO / 4.5-C / -PYRIDINE OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT; PHARMACEUTICAL PREPARATION.
US3193458A (en) Method of lowering blood cholesterol level
US3809761A (en) Method for reducing plasma lipid levels
US2939817A (en) Method of treating diseases associated with plasmin activity
Pedrique et al. Experimental and clinical studies with a new antimonial preparation for the treatment of schistosomiasis
US4942172A (en) Method of curing hepatic disease
US3894153A (en) Method of medical treatment of asthma
JPH0455167B2 (en)
EP0418674A1 (en) Pharmaceutical preparations for enhanced absorption of antibacterial compounds